LPCN (lipocine.com) יחס שווי שוק לשווי בספרים

Lipocine Inc. (LPCN) develops metabolic correction therapies while facing uncertainty due to patent disputes and potential regulatory rejections. The business relies on stable demand, with the current metric standing at 0.55. Long-term growth depends on test results and product commercialization. The share price fluctuations shown below are supplemented by data on production in Utah via third-party contractors.

This ratio determines the market revaluation of the company's net assets. By analyzing the relationship between market capitalization and book value, an investor identifies the premium for future growth. The metric is calculated by dividing the total equity value by the difference between assets and liabilities. For Lipocine Inc. (LPCN), a high variance reflects market expectations regarding its unique drug delivery platform. The current R&D stage makes this indicator a key measure of intellectual capital value.